首页> 外文期刊>BMC Cancer >The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression
【24h】

The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression

机译:低氧标志物作为乳腺分子成像靶标的潜力–人类标志物表达的系统评价和荟萃分析

获取原文
获取外文期刊封面目录资料

摘要

Background Molecular imaging of breast cancer is a promising emerging technology, potentially able to improve clinical care. Valid imaging targets for molecular imaging tracer development are membrane-bound hypoxia-related proteins, expressed when tumor growth outpaces neo-angiogenesis. We performed a systematic literature review and meta-analysis of such hypoxia marker expression rates in human breast cancer to evaluate their potential as clinically relevant molecular imaging targets. Methods We searched MEDLINE and EMBASE for articles describing membrane-bound proteins that are related to hypoxia inducible factor 1α (HIF-1α), the key regulator of the hypoxia response. We extracted expression rates of carbonic anhydrase-IX (CAIX), glucose transporter-1 (GLUT1), C-X-C chemokine receptor type-4 (CXCR4), or insulin-like growth factor-1 receptor (IGF1R) in human breast disease, evaluated by immunohistochemistry. We pooled study results using random-effects models and applied meta-regression to identify associations with clinicopathological variables. Results Of 1,705 identified articles, 117 matched our selection criteria, totaling 30,216 immunohistochemistry results. We found substantial between-study variability in expression rates. Invasive cancer showed pooled expression rates of 35% for CAIX (95% confidence interval (CI): 26-46%), 51% for GLUT1 (CI: 40-61%), 46% for CXCR4 (CI: 33-59%), and 46% for IGF1R (CI: 35-70%). Expression rates increased with tumor grade for GLUT1, CAIX, and CXCR4 (all p Conclusions Our results support the potential of hypoxia-related markers as breast cancer molecular imaging targets. Although specificity is promising, combining targets would be necessary for optimal sensitivity. These data could help guide the choice of imaging targets for tracer development depending on the envisioned clinical application.
机译:背景技术乳腺癌的分子成像是一种有前途的新兴技术,有可能改善临床护理。分子成像示踪剂开发的有效成像目标是膜结合的缺氧相关蛋白,当肿瘤生长超过新血管生成时表达。我们进行了系统的文献综述和这种低氧标志物在人类乳腺癌中的表达率的荟萃分析,以评估其作为临床相关分子成像靶标的潜力。方法我们在MEDLINE和EMBASE上搜索了描述与缺氧诱导因子1α(HIF-1α)相关的膜结合蛋白的文章,HIF-1α是缺氧反应的关键调节因子。我们提取了碳酸酐酶IX(CAIX),葡萄糖转运蛋白1(GLUT1),CXC趋化因子受体4型(CXCR4)或胰岛素样生长因子1受体(IGF1R)在人乳腺疾病中的表达率,通过评估免疫组织化学。我们使用随机效应模型汇总了研究结果,并应用了元回归来确定与临床病理变量的关联。结果在1,705篇鉴定的文章中,有117篇符合我们的选择标准,总计30,216份免疫组织化学结果。我们发现大量的研究之间的表达率差异。浸润性癌显示CAIX的合并表达率为35%(95%置信区间(CI):26-46%),GLUT1为51%(CI:40-61%),CXCR4为46%(CI:33-59%) )和IGF1R的46%(CI:35-70%)。 GLUT1,CAIX和CXCR4的表达水平随肿瘤级别的增加而增加(所有p结论结论我们的结果支持与缺氧相关的标志物作为乳腺癌分子成像靶标的潜力。尽管特异性是有希望的,但组合靶标对于获得最佳敏感性是必要的。这些数据根据所设想的临床应用,可以帮助指导选择用于示踪剂开发的成像目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号